Stocktoria
Trulieve Cannabis Corp. TRLV
NYSE · XNYS · stock · Medicinal Chemicals & Botanical Products · website · IPO 2018-09-25
Chart by TradingView
4/9
Piotroski F — financial health
1.09
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials & ratios (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Financials | |||||
| Revenue | $1.2B | $1.2B | $1.1B | $1.2B | $931.9M |
| Gross profit | $711.2M | $715.7M | $588.6M | $689.1M | $566.6M |
| Operating income | $143.5M | $97.8M | -$221.6M | $50.2M | $204.1M |
| Net income | — | — | — | -$252.7M | $17.4M |
| Operating cash flow | $272.8M | $271.5M | $201.8M | $23.1M | $12.9M |
| Free cash flow | $228.6M | $148.9M | $161.6M | -$141.7M | -$263.0M |
| Total assets | $2.7B | $2.9B | $2.7B | $3.4B | $3.4B |
| Total liabilities | $1.6B | $1.6B | $1.3B | $1.5B | $1.3B |
| Shareholders' equity | $1.1B | $1.2B | $1.4B | $1.9B | $2.1B |
| Ratios | |||||
| Gross margin | 60.2% | 60.3% | 52.1% | 56.6% | 60.8% |
| Operating margin | 12.1% | 8.2% | -19.6% | 4.1% | 21.9% |
| Net margin | — | — | — | -20.7% | 1.9% |
| FCF margin | 19.4% | 12.5% | 14.3% | -11.6% | -28.2% |
| Return on assets | — | — | — | -7.4% | 0.5% |
| Return on equity | — | — | — | -13.1% | 0.8% |
| Debt / equity | 0.12× | 0.29× | 0.26× | 0.28× | 0.22× |
| Current ratio | 4.43 | 4.37 | 4.16 | 2.82 | 3.10 |
| Revenue growth | -0.4% | 5.1% | -7.3% | 30.7% | 78.7% |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 1.09 (distress)
- Working capital / assets 0.162
- Retained earnings / assets -0.338
- EBIT / assets 0.053
- Equity / liabilities 0.736
Sector peers
VFS · TM · HMC · SONY · AAPL · XOM · all Manufacturing →
Source: SEC EDGAR filings · CIK 0001754195 · as of 2025-12-31. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.